Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge - 10/08/11
, Robert A. Wood, MD b, Deepen Patel, MD c, Jin Zhu, PhD d, Ashley Yegin, MD d, Gitika Dhillon, MD b, James E. Fish, MD d
Reprint requests: Jonathan Corren, MD, Allergy Medical Clinic, Research Division, 10780 Santa Monica Blvd, Suite 280, Los Angeles, CA 90025.Abstract |
Background |
Environmental exposure to cat allergen is common, and sensitization to cat allergens is strongly associated with asthma.
Objective |
We sought to examine the efficacy of omalizumab in preventing acute bronchoconstriction induced by environmental exposure to cat allergen.
Methods |
Patients with a history of cat allergen–induced asthma were randomized to treatment with omalizumab or placebo and exposed to cat allergen in a controlled chamber for up to 1 hour at baseline and after 16 weeks of treatment. The primary efficacy outcome was area under the curve for percentage decrease from prechallenge FEV1 at week 16 for omalizumab-treated versus placebo-treated patients. FEV1 was recorded before and every 10 minutes during the 1-hour challenge. Chest, nasal, and ocular symptoms were also monitored during cat chamber exposure as secondary end points.
Results |
The area under the curve for percentage decrease in FEV1 was 15.2% per hour for omalizumab-treated patients (n = 32) and 27.3% per hour for placebo-treated patients (n = 33), reflecting 44% less reduction in FEV1 and a treatment difference of −12.1% per hour (P = .0009; 95% CI, −19.0 to −5.2). Compared with placebo-treated patients, omalizumab-treated patients were also able to tolerate longer allergen exposure (P = .0006) and demonstrated significant reductions from prechallenge values in their chest symptom score (P < .0001) and nasal-ocular symptom score (P = .0002).
Conclusions |
The severity of acute airway reactions and symptoms caused by controlled cat room exposure to allergens was significantly reduced by treatment with omalizumab.
Le texte complet de cet article est disponible en PDF.Key words : Aeroallergen, cat allergy, dander, Fel d 1, omalizumab, IgE, asthma
Abbreviations used : ANCOVA, AUC, NOSS
Plan
| Supported by Genentech, Inc. |
|
| Disclosure of potential conflict of interest: J. Corren has given talks for Genentech and has received research support from Genentech and Novartis. R. A. Wood has received research support from the National Institutes of Health and Genentech and is on the medical advisory board of the Food Allergy and Anaphylaxis Network. D. Patel is an employee of Cetero Research and has received research support from Genentech. J. Zhu, A. Yegin, and J. E. Fish are employees of Genentech. G. Dhillon has declared no conflict of interest. |
Vol 127 - N° 2
P. 398-405 - février 2011 Retour au numéro
Article précédent
- Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies
- Adnan Custovic, Janet Rothers, Debbie Stern, Angela Simpson, Ashley Woodcock, Anne L. Wright, Nicolaos C. Nicolaou, Jenny Hankinson, Marilyn Halonen, Fernando D. Martinez
- The Madison Avenue effect: How drug presentation style influences adherence and outcome in patients with asthma
- Emmanuelle M. Clerisme-Beaty, Susan J. Bartlett, W. Gerald Teague, John Lima, Charles G. Irvin, Rubin Cohen, Mario Castro, Robert A. Wise, Cynthia S. Rand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?